Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178463 | 0.86 | LOXL2 (0.40) | LOXL2CYP4F2CYP4A11RORCMAPT | |
| SCHEMBL16178580 | 0.82 | CA1 (0.44) | ALDH1A1 | |
| SCHEMBL14861439 | 0.82 | LOXL2 (0.55) | LOXL2CYP4F2CYP4A11RORCSLC7A5 | |
| Hydrochloric Acid SCHEMBL16178563 | 0.82 | CYP19A1 (0.34) | — | |
| SCHEMBL16178562 | 0.82 | CYP2C19 (0.42) | RORCMAPTRAB9AALDH1A1TSHR | |
| SCHEMBL3932525 | 0.73 | LOXL2 (0.66) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL35360 | 0.71 | LOXL2 (0.64) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL9893361 | 0.71 | LOXL2 (0.42) | LOXL2CYP4F2CYP4A11SLC7A5MAPT | |
| SCHEMBL12459396 | 0.70 | LOXL2 (0.67) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL5969642 | 0.70 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371337-B2 | β-lactamase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140315861-A1 | BETA-LACTAMASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315861-A1 | BETA-LACTAMASE INHIBITORS | BTD, GUSB, BLVRB | LOXL2 1054/4885CYP4F2 2301/4885CYP4A11 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.